Multi-Modality Guided Prostate Biopsy

Novel imaging probes will help to detect small lesions that will require accurate and precise multimodality-guided biopsy with a spatial accuracy of ~2mm to allow tissue acquisition and treatments to be tailored to the unique spatial/biologic distribution of cancer lesions for an individual patient. In the first cycle of OICR funding, our multi-disciplinary team developed a 3D ultrasound-guided prostate biopsy system for improving prostate cancer (PCa) diagnosis. Patents describing this technology have been filed and the technology has been licensed to Eigen for worldwide distribution. In this Project, we propose to extend these efforts through our over-arching hypothesis, which is that combining multi-modality imaging of sensitive imaging probes with accurate multi-modality guided biopsy procedures will improve diagnosis of clinically relevant cancers at curable stages. During the past OICR funding cycle, we have identified two aspects of the system that must be developed, optimized and tested to be able to achieve the full benefit of a multi-modality guided prostate biopsy system. We have identified two related sources of guidance errors that must be solved, prostate deformation and motion. These are caused by the ultrasound transducer as it is being manipulated and patient motion in response to pain during the biopsy; in addition to different prostate deformation caused by different imaging modalities (i.e., MR and US).